Funding Overview
mbiomics, a Munich-based microbiome therapeutics company, raised €30 million ($33 million) in Series A funding to advance its precision microbiome platform and lead therapeutic programs. The funding will support clinical development of lead candidates for inflammatory and metabolic diseases.
The round was led by Bio-Vision Partners with participation from Munich Venture Partners, Nordic Biotechnology Fund, and founding investor Helvetica Capital. The financing values the company at approximately €120 million post-money, reflecting significant confidence in the precision microbiome approach.
This substantial Series A financing enables mbiomics to advance multiple therapeutic programs through clinical proof-of-concept while establishing commercial-scale manufacturing capabilities. The microbiome therapeutics field has matured significantly, with multiple programs demonstrating clinical signals supporting investment.
Microbiome Therapeutics Opportunity
The human microbiome—trillions of bacteria, viruses, and fungi living in and on our bodies—has emerged as a key regulator of health and disease. Research over the past two decades has established that the microbiome influences metabolism, immune function, neurological health, and disease susceptibility through complex interactions with host physiology.
Dysbiosis, abnormal microbial community composition, has been linked to inflammatory bowel disease, metabolic syndrome, neurological conditions, autoimmune disorders, and even cancer. Understanding these associations has created unprecedented opportunities for therapeutic intervention through microbiome modulation.
Microbiome therapeutics aim to restore healthy microbial communities through defined bacterial formulations. Early approaches used fecal microbiota transplantation (FMT), which demonstrated remarkable efficacy particularly for Clostridioides difficile infection but raised significant safety concerns regarding pathogen transmission and regulatory complexity.
Precision microbiome approaches using defined bacterial consortia offer potential for standardized, safe, and scalable therapeutics. However, identifying the right bacterial combinations and manufacturing them consistently at scale has proven scientifically and technically challenging, requiring significant platform investment.
mbiomics Platform
mbiomics has developed a comprehensive platform combining high-throughput microbiome profiling, machine learning-driven target identification, and proprietary manufacturing capabilities. The platform enables identification of therapeutic bacterial combinations and scalable manufacturing to support clinical development.
The platform integrates proprietary bacterial strain libraries containing thousands of characterized isolates from multiple body sites, computational target identification using machine learning models trained on extensive clinical datasets, scalable manufacturing using proprietary fermentation and lyophilization processes ensuring consistent product quality, and clinical biomarkers enabling patient stratification and treatment response prediction.
The company has generated clinical data across multiple therapeutic areas, demonstrating consistent safety and preliminary efficacy signals supporting advancement of lead programs into later-stage clinical development.
Research Foundation
The platform was developed through more than a decade of research at leading European research institutions, with foundational work published in leading journals including Nature Medicine, Cell, and The Lancet. The company has accumulated extensive intellectual property protecting its platform technology and therapeutic approaches.
Research has established clear associations between microbiome composition and multiple disease states, identified bacterial strains with therapeutic potential, and demonstrated manufacturing reproducibility required for pharmaceutical development.
Lead Programs
The company is advancing multiple therapeutic programs across high-value indications:
- MBL-101 (IBD): Inflammatory bowel disease program, with Phase 2 trials planned for ulcerative colitis
- MBL-202 (Metabolic): Metabolic syndrome program, with Phase 1 complete demonstrating safety and preliminary efficacy
- MBL-301 (Dermatology): Atopic dermatitis program, in preclinical development
Clinical Data
The company has completed multiple clinical studies demonstrating safety and signals of efficacy. In ulcerative colitis, MBL-101 showed clinical remission rates exceeding placebo in Phase 1b studies, with improvements in microbiome diversity correlating with clinical response.
In the metabolic syndrome program, MBL-202 demonstrated improvements in insulin sensitivity and reductions in markers of systemic inflammation in Phase 1 studies. These results support advancement into larger Phase 2 trials.
Manufacturing has been demonstrated at commercial scale with consistent product quality, addressing a key challenge in the microbiome therapeutics field. The company operates GMP facilities in Munich suitable for late-stage clinical and early commercial supply.
Regulatory Strategy
mbiomics is pursuing regulatory approval through standard pharmaceutical development pathways. The company has met with regulatory authorities in Europe and the US to align on clinical development plans and manufacturing requirements.
Lead programs target inflammatory bowel disease and metabolic syndrome, both significant unmet medical needs with substantial patient populations. Regulatory pathways have been established through dialogue with FDA and EMA.
Leadership
Founded by Elena Schmidt, PhD, and Thomas Kraft, MBA, the team combines extensive microbiome science expertise with significant biotech commercialization experience. Elena Schmidt serves as CEO, bringing 20 years of drug development experience including leadership roles at Roche and MorphoSys.
Thomas Kraft serves as Chief Operating Officer, managing operations and manufacturing. His background includes extensive experience in biopharmaceutical manufacturing and operations at leading Swiss pharmaceutical companies.
The team has grown to over 80 employees across research, clinical, manufacturing, and commercial functions. Key hires include experienced drug developers from leading pharmaceutical and biotech companies.
Funding Allocation
The €30 million Series A will support advancement of lead programs through clinical proof-of-concept, expansion of manufacturing capabilities, and continued platform development. Funding will support Phase 2 trials for MBL-101 in ulcerative colitis and Phase 2 trials for MBL-202 in metabolic syndrome.
The company will also invest in expanding its strain library and refining its computational platform for target identification and patient stratification.
Business Model
mbiomics plans to develop therapeutic programs through initial clinical validation, with the option to pursue partnerships with major pharmaceutical companies for broader commercialization. The precision approach enables patient stratification and targeted therapy matching.
Target pricing for microbiome therapeutics could range from $10,000-$50,000 per treatment course depending on indication and clinical results, representing significant discounts to biologic therapeutics while providing margins supporting commercial success.
The company may pursue accelerated approval pathways for orphan indications where microbiome approaches have demonstrated significant clinical benefit.
Market Opportunity
The microbiome therapeutics market is projected to exceed $10 billion by 2030, driven by increasing understanding of microbiome-disease associations and clinical validation of therapeutic approaches. Key growth areas include inflammatory bowel disease, metabolic disease, and dermatological conditions.
The addressable patient population for mbiomics' lead indications exceeds 50 million patients in the major markets, representing substantial commercial opportunity if clinical trials demonstrate efficacy.
Related companies advancing microbiome therapeutics demonstrate continued pharmaceutical industry interest in this modality. Finch Therapeutics continues advancing microbiome therapies, and Vedanta Biosciences continues developing defined microbiome products, representing competitive activity in this space.
Competitive Landscape
Current competition in microbiome therapeutics includes fecal microbiota transplantation approaches (limited by safety and regulatory challenges), defined consortia approaches (mbiomics and competitors), single-strain approaches (limited efficacy), and microbial metabolites (emerging approach).
mbiomics' competitive advantages include comprehensive platform capabilities, clinical-stage development with demonstrated safety, scalable manufacturing, and proprietary strain libraries supporting continued program advancement.
Looking Ahead
mbiomics is well-positioned to advance precision microbiome therapeutics through clinical development. The company's success depends on demonstrating reproducible efficacy in controlled clinical trials and establishing partnerships for global commercialization.
The team plans to pursue parallel clinical development across multiple indications following initial clinical proof-of-concept, leveraging the platform's capabilities to identify and advance additional therapeutic programs.
Future priorities include expanding clinical programs, establishing commercial partnerships, and continuing platform development to enable precision patient selection.